Haloperidol/ondansetron/opioid analgesics interaction
- PDF / 169,854 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 203 Views
1 XS
Serotonin syndrome and persistent tachycardia: 2 case reports In a 5-year single-centre retrospective study of 51 patients conducted between 01 January 2013 to 26 April 2018, who were admitted to the burn unit at the Southmead Hospital UK, two patients [including 1 adult patient; sexes not stated; not all ages stated] were described, who developed serotonin syndrome or persistent tachycardia following concomitant administration of haloperidol, ondansetron, fentanyl or tramadol as antipsychotic or anti-emetic therapy [not all indications, routes and outcomes stated; dosage and duration of treatments to reaction onsets not stated]. A patient was admitted to the burn unit for the treatment of burns. The patient had been receiving antipsychotic therapy with oral haloperidol, and anti-emetic treatment with ondansetron. However, over the first 5 days, the patient developed persistent tachycardia with a HR of 120–135 beats/minute secondary to drug interaction between ondansetron and haloperidol. An ECG revealed tachycardia of 132 beats/minute; however, the rhythm could not be interpreted properly as the leads could not be cited due to severe chest burns. The interaction was graded severe as per Stockley’s interaction checker scale. An adult patient presented to the burn unit with toxic epidermal necrolysis. The patient was hospitalised, and started receiving tramadol and fentanyl along with other unspecified medications. Thereafter, the patient developed serotonin syndrome secondary to drug interaction between tramadol and fentanyl. However, the symptoms resolved rapidly. Al-Khalil M, et al. A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities. Burns 46: 1043-1050, No. 5, 803502004 Aug 2020. Available from: URL: http://doi.org/10.1016/j.burns.2020.01.010
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
